AKBA Akebia Therapeutics Inc

Price (delayed)

$0.3652

Market cap

$67.03M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.6

Enterprise value

$22.89M

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is ...

Highlights
Akebia Therapeutics's EPS has increased by 42% YoY and by 6% from the previous quarter
AKBA's net income is up by 30% YoY and by 2.5% from the previous quarter
The company's quick ratio fell by 47% YoY but it rose by 21% QoQ
Akebia Therapeutics's revenue has decreased by 14% YoY but it has increased by 4.4% QoQ
The equity has dropped by 88% year-on-year and by 66% since the previous quarter
AKBA's debt is up by 9% year-on-year

Key stats

What are the main financial stats of AKBA
Market
Shares outstanding
183.53M
Market cap
$67.03M
Enterprise value
$22.89M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.53
Price to sales (P/S)
0.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.1
Earnings
Revenue
$222.97M
EBIT
-$255.49M
EBITDA
-$219.52M
Free cash flow
-$203.95M
Per share
EPS
-$1.6
Free cash flow per share
-$1.14
Book value per share
$0.14
Revenue per share
$1.24
TBVPS
$2.12
Balance sheet
Total assets
$535.36M
Total liabilities
$509.24M
Debt
$130.43M
Equity
$26.12M
Working capital
$48.77M
Liquidity
Debt to equity
4.99
Current ratio
1.19
Quick ratio
0.94
Net debt/EBITDA
0.2
Margins
EBITDA margin
-98.5%
Gross margin
32.7%
Net margin
-123.6%
Operating margin
-116.1%
Efficiency
Return on assets
-48.5%
Return on equity
-266.1%
Return on invested capital
-223%
Return on capital employed
-90.8%
Return on sales
-114.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AKBA stock price

How has the Akebia Therapeutics stock price performed over time
Intraday
-7.12%
1 week
6.81%
1 month
15.02%
1 year
-91.26%
YTD
-83.84%
QTD
-49.13%

Financial performance

How have Akebia Therapeutics's revenue and profit performed over time
Revenue
$222.97M
Gross profit
$72.84M
Operating income
-$258.88M
Net income
-$275.68M
Gross margin
32.7%
Net margin
-123.6%
The operating income is up by 32% year-on-year and by 2.4% since the previous quarter
AKBA's net income is up by 30% YoY and by 2.5% from the previous quarter
AKBA's gross profit is up by 21% since the previous quarter
The operating margin has grown by 21% YoY and by 7% from the previous quarter

Growth

What is Akebia Therapeutics's growth rate over time

Valuation

What is Akebia Therapeutics stock price valuation
P/E
N/A
P/B
2.53
P/S
0.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.1
Akebia Therapeutics's EPS has increased by 42% YoY and by 6% from the previous quarter
The equity has dropped by 88% year-on-year and by 66% since the previous quarter
AKBA's P/B is 41% below its last 4 quarters average of 4.3 and 28% below its 5-year quarterly average of 3.5
The price to sales (P/S) is 91% less than the 5-year quarterly average of 3.2 and 85% less than the last 4 quarters average of 1.9
Akebia Therapeutics's revenue has decreased by 14% YoY but it has increased by 4.4% QoQ

Efficiency

How efficient is Akebia Therapeutics business performance
Akebia Therapeutics's return on equity has shrunk by 95% YoY and by 42% QoQ
Akebia Therapeutics's ROS has increased by 22% YoY and by 7% from the previous quarter
The ROA has grown by 17% YoY
The return on invested capital has declined by 8% since the previous quarter

Dividends

What is AKBA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AKBA.

Financial health

How did Akebia Therapeutics financials performed over time
AKBA's total assets is 5% greater than its total liabilities
The company's quick ratio fell by 47% YoY but it rose by 21% QoQ
Akebia Therapeutics's current ratio has decreased by 44% YoY but it has increased by 12% QoQ
The debt to equity has surged by 190% since the previous quarter
The equity has dropped by 88% year-on-year and by 66% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.